Cagrilintide
AM833 · CagriSema (with semaglutide) · Long-acting amylin analogue
A long-acting amylin analogue in Phase III clinical trials, studied for weight management and metabolic disease, often in combination with semaglutide (CagriSema) for synergistic weight reduction.
Half-Life
~7 days (albumin-binding extended)
MW
~4700 Da
Amino Acids
38 AA
Evidence
Moderate Evidence
Regulatory Status
Investigational. Not FDA/EMA approved as of 2025. Phase III clinical trials ongoing (CagriSema for obesity).
In Plain English
A once-a-week version of the amylin hormone signal your pancreas makes to tell you to stop eating. Combined with semaglutide (which also reduces hunger via a different pathway), the two together produce weight loss greater than either drug alone — they hit hunger from two angles simultaneously.
Overview
Cagrilintide (AM833, Novo Nordisk) is an investigational long-acting amylin receptor agonist engineered for once-weekly subcutaneous dosing. Where pramlintide requires multiple daily injections and has a short half-life, cagrilintide is fatty acid-conjugated for albumin binding, extending its half-life to approximately one week. Phase II trial data showed significant weight reduction as monotherapy. The combination of cagrilintide with semaglutide ("CagriSema") demonstrated up to 15% body weight reduction in Phase II and is advancing through Phase III trials as a potential next-generation obesity treatment.
Common Formats
- Injectable subcutaneous (research/trial)
- Lyophilized powder (research)
Storage Notes
Refrigerate per trial protocol. Research compound — follow investigational brochure guidance.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Cagrilintide.
Research Sources
(3 vendors)For research use only. No affiliation or endorsement implied.
Related Compounds
Semaglutide
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
Pramlintide
An FDA-approved synthetic analogue of the pancreatic hormone amylin, used as an adjunct to insulin therapy in type 1 and type 2 diabetes, with research interest in weight management and satiety.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.
Retatrutide
A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.